Document:

exv10wqq

EXHIBIT
10.QQ

June 4, 2009

[INSERT NAME]

     Dear Mr. [INSERT LAST NAME],

     You and Skyworks Solutions, Inc. (the “Company”) are parties to a Performance Share Award
Agreement dated November 6, 2007 (your “2007 PSA”) evidencing the grant to you of an award of up to
[INSERT NUMBER OF SHARES] performance shares of the Company. Each such performance share represents
the right to receive one share of the common stock, $0.25 par value per share, of the Company
(“Common Stock”) upon, and to the extent of, the achievement of the performance metrics set forth
in your 2007 PSA.

     The Compensation Committee of the Board of Directors of the Company has determined to offer
you the opportunity to exchange your 2007 PSA for the following:

          (1) a new restricted stock award (the “2009 RSA”) for [INSERT NUMBER OF SHARES] shares of
restricted Common Stock equal to the “Nominal” tranche of shares of Common Stock that could be
earned under your 2007 PSA, which will vest on November 6, 2010, provided that you continue your
employment with the Company through such date, and

          (2) a new performance share award (the “2009 PSA” and together with the 2009 RSA, the “2009
Awards”) for up to [INSERT NUMBER OF SHARES] performance shares of the Company (the aggregate
amount of the “Target” and “Stretch” tranches of shares of Common Stock that could be earned under
the 2007 PSA), each of which will represent the right to receive one share of Common Stock upon the
satisfaction of the performance metrics and other conditions set forth on Exhibit A hereto.

     If you accept this offer to exchange your 2007 PSA for the 2009 Awards, you hereby agree as
follows:

          (1) that the 2009 Awards will be subject to the terms and conditions of the Company’s Amended
and Restated 2005 Long-Term Incentive Plan (the “Plan”);

 

 

          (2) that the 2009 Awards will be granted pursuant to applicable agreements between you and us
and will be subject to the additional terms and conditions set forth therein;

          (3) that your 2007 PSA will be cancelled effective as of the date of your execution of this
letter agreement and you, on behalf of yourself and your successors and assigns, fully, forever,
irrevocably and unconditionally forfeit, release, remise, waive and discharge with prejudice (a)
any and all of your rights with respect to, and your interest in, your 2007 PSA, (b) the Company
and its directors, officers, employees, agents, affiliates, subsidiaries, representatives,
successors and assigns from any and all of their obligations under, with respect to, or arising out
of, your 2007 PSA and (c) any and all claims, complaints, rights, causes of action, suits, demands,
expenses, costs or damages, both known and unknown, in law or in equity that you had, now have or
may have related to or arising out of your 2007 PSA;

          (4) that the transactions contemplated by this letter agreement and the vesting events
described hereby do not constitute an express or implied promise of continued engagement as an
employee or consultant for the vesting period, for any period, or at all; and

          (5) that you have been adequately represented by counsel or have voluntarily chosen not to
consult with counsel in deciding to accept this offer and execute this letter agreement.

     If you wish to accept this offer, you must counter-sign this letter agreement below and return
this form prior to June 9, 2009, to

          Mark V.B. Tremallo

          V.P., General Counsel

          Skyworks Solutions, Inc.

          20 Sylvan Road

          Woburn, MA 01801

     If we do not receive your signed written response by June 9, 2009, you will be deemed to have
rejected this offer. If you decide not to accept the offer, your 2007 PSA will continue in full
force and effect.

     This letter agreement, the Plan and the agreements governing the 2009 Awards constitute the
entire agreement between the parties, and supersede all prior agreements and understandings,
relating to the subject matter of this letter agreement. Notwithstanding anything to the contrary
in this letter agreement, in the event of any conflict between the terms of this letter agreement
and the Plan or the agreements governing the 2009 Awards, the Plan or the agreements governing the
2009 Awards, as applicable, shall control. This letter agreement shall be construed, interpreted
and enforced in accordance with the internal laws of the State of Delaware without regard to any
applicable conflicts of laws. This letter agreement may be executed in counterparts, each of which
will be deemed to be an original instrument and all such counterparts shall together constitute the
same agreement. The invalidity or unenforceability of any provision of this agreement shall not
affect the validity or enforceability of any other provision of this agreement, and each other
provision of this agreement shall be severable and enforceable to the extent permitted by law.
This letter agreement may be amended or modified only by a written instrument executed by both
parties hereto.

2

 

     If you have any questions about the offer please feel free to contact George LeVan.

     

	 	 	 	 	 
	 	SKYWORKS SOLUTIONS, INC.
 	 
	 	By:  	
 	 
	 	Name:  	Mr. Dave Aldrich 	 
	 	Title:  	President and CEO 	 
	 

	 	 	 	 	 
	AGREED AND ACCEPTED:	 	 
	 
	 	 	 	 
	 	 	 
	 
	 	 	 	 
	Name: [INSERT NAME]	 	 
	 
	 	 	 	 
	Dated:
	 	 	 	 
	 

	 	 

	 	 

3

 

Exhibit A

2009 Performance Share Award Conditions

Subject to the terms and conditions of the definitive agreement that governs the 2009 PSA and the
terms and conditions of the Plan, you will be issued one share of Common Stock for each performance
share that you are granted in the event that the following conditions are satisfied:

(a) Relative Stock Price Performance Condition:

     “Target Relative Stock Price” The “Target Relative Stock Price” metric shall be deemed met on
November 6, 2010 (the “Measurement Date) if the percentage change in the price of Skyworks’ common
stock exceeds the 60th percentile of its Peer Group (as defined below) during the Measurement
Period.

     “Stretch Relative Stock Price” The “Stretch Relative Stock Price” metric shall be deemed met
on the Measurement Date if the percentage change in the price of Skyworks’ common stock exceeds the
70th percentile of its Peer Group during the Measurement Period.

     For purposes of this agreement, the “Peer Group” shall consist of the following companies:

Anadigics, Inc.

Analog Devices, Inc.

Broadcom Corp.

Cypress Semiconductor Corporation

Fairchild Semiconductor Corp.

Integrated Device Technology, Inc.

Intersil Corporation

Linear Technology Corporation

LSI Logic Corporation

Maxim Integrated Products, Inc.

National Semiconductor Corporation

ON Semiconductor Corp.

RF Micro Devices, Inc.

Silicon Laboratories Inc.

TriQuint Semiconductor, Inc.

     For purposes of this agreement, the Measurement Period shall begin on November 6, 2007, and
end on the Measurement Date, and the percentage change in the price of the common stock of the
Company, as well as each member of the Peer Group, during such period shall be determined by
comparing (x) the average of the entity’s stock price for the ninety (90) day period beginning on
November 6, 2007 to (y) the average of the entity’s stock price for the ninety (90) day period
ending on the Measurement Date. For purposes of calculating the average price of the common stock
of an entity during such ninety (90) day periods, only “trading days” shall be used in the
calculation and trading volume on any such trading day shall not be factored into such calculation.

4

 

(b) Continued Employment Condition.

     If the Relative Stock Price Performance Metric is met for either the “Target” or “Stretch”
tranche (or both), then 50% of such total shares would be issuable to the participant on 11-6-2010,
and the other 50% of such total shares would be issuable on 11-6-2011, provided that the
participant has continued employment with Skyworks through such date(s).

5exv4w2

EXHIBIT 4.2

CERTIFICATE OF AMENDMENT OF

SECOND AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION OF

CYPRESS BIOSCIENCE, INC.

     Cypress Bioscience, Inc., a corporation organized and existing under and by virtue of the
General Corporation Law of the State of Delaware, hereby certifies that:

     One: The name of this corporation is Cypress Bioscience, Inc. and the date of filing
the original Certificate of Incorporation of this corporation with the Secretary of State of the
State of Delaware was October 21, 1981 under the name Immune Response Systems, Inc. The
Certificate of Incorporation was subsequently amended and restated on April 18, 1996 under the name
IMRÉ Corporation and was subsequently amended on September 16, 1999, March 9, 2001 and amended and
restated on September 22, 2003 (collectively, the
“Certificate of Incorporation”).

     Two: The Board of Directors of the Company (the “Board”), acting in accordance with
the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware,
adopted resolutions amending the Company’s Certificate of Incorporation as follows:

Section A of Article IV shall be amended and restated to read in its
entirety as follows:

This Corporation is authorized to issue two classes of stock to be
designated, respectively, “Common Stock” and “Preferred Stock.” The
total number of shares which the Corporation is authorized to issue
is 105,000,000 shares. 90,000,000 shares shall be Common Stock,
each having a par value of $.001. 15,000,000 shares shall be
Preferred Stock, each having a par value of $.001.

     Three: Thereafter pursuant to a resolution of the Board, this Certificate of
Amendment was submitted to the stockholders of the Company for their approval, and was duly adopted
in accordance with the provisions of Section 242 of the General Corporation Law of the State of
Delaware.

     In Witness Whereof, the Company has caused this Certificate of Amendment to be signed
by its Executive Vice President, Chief Operating Officer and Chief Financial Officer this 15th day
of June 2009.

	 	 	 	 	 
	 	Cypress Bioscience, Inc.

 	 
	 	By:  	/s/ Sabrina Martucci-Johnson
 	 
	 	 	Sabrina Martucci-Johnson 	 
	 	 	Executive Vice President,
Chief Operating 
Officer
and Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}]]